Truist raised the firm’s price target on BridgeBio (BBIO) to $86 from $80 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio initiated with an Overweight at Morgan Stanley
- BridgeBio Pharma: Emerging Rare Disease Leader With Robust Growth Outlook and Discounted Valuation Supporting Buy Rating
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
- Alnylam price target lowered to $351 from $370 at Leerink
- BridgeBio price target raised to $86 from $75 at Leerink